about
Physical and functional interaction between HCV core protein and the different p73 isoformsModulation of the vitamin D3 response by cancer-associated mutant p53The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiationInduction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cellsFrom p63 to p53 across p73.The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage.Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expressionMicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of functionIdentification of post-transcriptional regulatory networks during myeloblast-to-monocyte differentiation transition.miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours.Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.Argonaute 2 sustains the gene expression program driving human monocytic differentiation of acute myeloid leukemia cells.MicroRNAs and lymph node metastatic disease in lung cancer.Physical interaction with human tumor-derived p53 mutants inhibits p63 activities.ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters.Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses.Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop.The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1.The cyclin B1 gene is actively transcribed during mitosis in HeLa cells.Id2 gene is a transcriptional target of the protein complex mutant p53/E2F1.Altered peritumoral microRNA expression predicts head and neck cancer patients with a high risk of recurrence.DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes.Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma.S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation.deltaEF1 repressor controls selectively p53 family members during differentiation.MicroRNA expression as predictor of local recurrence risk in oral squamous cell carcinoma.Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress.Zebrafish as experimental model to establish the contribution of mutant p53 and ID4 to breast cancer angiogenesis in vivo.Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages.Down-regulation of cyclin B1 gene transcription in terminally differentiated skeletal muscle cells is associated with loss of functional CCAAT-binding NF-Y complexMutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cellsAllelic expression imbalance of TP53 mutated and polymorphic alleles in head and neck tumors
P50
Q24301094-5565A208-1178-47F9-8D37-FF1F68C8EED0Q24302430-2480601B-164F-4AB6-9596-337FC2C8FBCEQ24746257-DAB75131-CB0A-4830-A6F8-A9EAB0328B5CQ33963529-5D859114-0B2A-49B2-B357-582DD4894261Q34164614-750D13B6-A5A9-4B4B-ABA7-04D63AEEB41EQ34418866-980D534D-4510-4272-8800-9C2393566B21Q35742357-0C2FE854-0045-4FD1-8F79-37975729A5A3Q35965859-5A3E7F56-B1E3-44DD-BF7D-D4CC10D4E2D9Q36190268-5D98705D-873A-4CBD-AEA9-A15587462A62Q36389324-7ADCE997-7892-4799-82FA-A0C9E14AB95CQ37344081-F07822D0-7340-48CA-9335-65F66862D718Q37357102-62F4CFA2-4167-4A8C-B65D-4DF2FA564F18Q38004129-FD0EF2F0-6451-47F4-8ED9-9404D1F59FBBQ38291171-DCF35D76-6176-4634-A44F-511D54F4C89EQ38337212-55F0B075-E0C2-4682-A076-F09F120F699FQ38363282-413F5856-31A0-445A-92E9-BCF302487971Q39166823-115F0F2D-56D1-45A1-A756-A947C2D344A6Q39434450-F44906CC-81DB-4A07-A464-7577CCE1842EQ39794563-7EF97893-F52B-4B2D-9A25-5EFD5DA32E38Q42511555-B58B2BF7-A825-4A79-82C3-7D30A4D41C40Q42724508-1CB81AC1-B714-4C6C-AB73-0036AF25DB93Q44002243-DF3B8614-AF57-43A2-B9A9-3AEED56BCB29Q48088749-2D649B4F-3EB8-4C1A-8FD7-EBA922D1C922Q50320380-CE9B7884-2B9B-45CD-A6B1-29DFDE5C179DQ51416797-D3B68902-6BDD-4E77-8694-7CB0455D62F0Q52027067-90403075-D3E5-4B71-A09E-5E0F59731D61Q52044852-E8136BAD-05CA-4D6C-8BEB-EBB474E52CC2Q53226065-08140114-5022-4CE6-84DD-E366380D4120Q53730263-BF39BA1A-71C8-4E6C-B444-6D039A91C9C1Q55040918-FB559909-0178-43A6-BA7B-D53126302AE0Q55300491-1CDFC9B1-2B5E-4494-B6CF-2CE0EA571C71Q77853902-93C969AB-39DB-475B-8082-CAA8E526C906Q79961179-6C8662D3-E23E-4742-A121-464AC1BBCD07Q83470648-AC01CA04-881E-4089-BF32-F18F8089E82B
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giulia Fontemaggi
@ast
Giulia Fontemaggi
@en
Giulia Fontemaggi
@es
Giulia Fontemaggi
@nl
Giulia Fontemaggi
@sl
type
label
Giulia Fontemaggi
@ast
Giulia Fontemaggi
@en
Giulia Fontemaggi
@es
Giulia Fontemaggi
@nl
Giulia Fontemaggi
@sl
prefLabel
Giulia Fontemaggi
@ast
Giulia Fontemaggi
@en
Giulia Fontemaggi
@es
Giulia Fontemaggi
@nl
Giulia Fontemaggi
@sl
P1053
K-9702-2016
P106
P1153
6505955714
P21
P31
P3829
P496
0000-0001-8332-8842